Key Drivers
- Strong liquidity
- Loss-making operations
- Negative free cash flow
AIAI Summary
CYRX is a well-funded but unproven operating-leverage bet on cell-and-gene-therapy commercialization: investors should require sustained revenue growth to translate into meaningful EBITDA and free-cash-flow improvement before treating the rally near $17.13 as durable.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Loss-making operations
- •Negative free cash flow
CYRX has strong liquidity and gross margins, but recent operating losses, negative free cash flow, and weak earnings quality make the low headline valuation appear risky rather than clearly attractive.
Price Behavior
Key Price Behavior Insights:
- •Strong recent rally
- •Support holding firm
- •Resistance test ahead
CYRX has rallied sharply over the last month and remains bullish above $16.31 support, but needs to clear $17.13 resistance to sustain upside.
Rapid seven-of-eight-session advance raises profit-taking risk
Sentiment & News
Similar Companies in Industrials
Other companies in the same sector with AI ratings